We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Lee Honigberg - Senior Director and Principal Scientist, OMNI Biomarker Development

Lee Honigberg

Senior Director and Principal Scientist, OMNI Biomarker Development

"Genentech is a great place to do drug development – we test novel therapeutics for serious diseases and take an integrated approach to clinical development that is driven by a strong commitment to scientific integrity."
13
Years at Genentech
18
Publications at Genentech

I did my PhD in Neuroscience at UCSF and then started at a small company using C. elegans to discover new drug targets for neuropathic pain. That company was subsequently acquired by Celera Genomics where I continued to work in drug discovery across several therapeutic areas. After Celera, I moved further toward the clinic, leading the preclinical and biomarker development for a Btk inhibitor at Pharmacyclics. I joined Genentech in 2009 to return to Neuroscience and focus on biomarkers.

Featured Publication

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

Mol Neurodegener. 2014; 9: 22. Published online 2014 Jun 6.

Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA.